|
HALL B
|
|
|
10:30-11:40
|
Pediatric Thrombosis: Assessment of risk factors
|
|
Chairpersons
|
Gili Kenet, Israel
Ulrike Nowak-Gottl, Germany
|
|
10:30-10:50
|
State of the Art: Genome-wide association studies in pediatric stroke and venous thrombosis
Monika Stoll, Germany
|
10:50-11:40
10:50
11:10
11:30 |
Debate: Should thrombophilia be tested in children with provoked thrombosis?
Yes: Ulrike Nowak-Gottl, Germany
No: Heleen Van Ommen, The Netherlands
Discussion |
|
HALL A
|
|
|
14:00-16:00
|
Pediatric thromboembolism: Therapeutic approach
|
|
Chairpersons
|
Shoshana Revel-Vilk, Israel
Heleen Van Ommen, The Netherlands |
|
14:00-14:50
14:00
14:20
14:40
|
Debate: Is there a role for primary anticoagulant prophylaxis in children with leukemia and central venous lines?
Yes: Angelo Claudio Molinari, Italy
No: Shoshana Revel-Vilk, Israel
Discussion
|
|
14:50-15:10
|
State of the Art: Deep vein thrombosis and the risk for post-thrombotic syndrome in infants and children
Shoshana Revel-Vilk, Israel |
|
15:10-16:00
15:10
15:30
15:50
|
Debate: Should infants with perinatal thrombosis be treated with anticoagulants?
Yes: Heleen Van Ommen, The Netherlands
No: Tzipi Strauss, Israel
Discussion
|
Saturday, November 7, 2015
|
HALL B
|
|
|
10:50-13:00
|
Hemophilia and bleeding in children
|
|
Chairpersons
|
Kathelijn Fischer, The Netherlands
Rolf C.R. Ljung, Sweden
|
|
10:50-11:10
|
State of the Art: Prophylaxis in the era of new factor concentrates
Kathelijn Fischer, The Netherlands
|
|
11:10-12:05
11:10
11:30
11:50
|
Debate: Longer acting new factor concentrates would be the future of pediatric
hemophilia care
Yes: Kathelijn Fischer, The Netherlands
No: Rolf C.R. Ljung, Sweden
Discussion
|
|
12:05-13:00
12:05
12:25
12:45
|
Debate: Should children with severe FVII deficiency get primary prophylaxis?
Yes: Amir Kuperman, Israel
No: Ophira Salomon, Israel
Discussion
|
